LEGN
Income statement / Annual
Last year (2023), Legend Biotech Corporation's total revenue was $285.14 M,
an increase of 143.70% from the previous year.
In 2023, Legend Biotech Corporation's net income was -$518.25 M.
See Legend Biotech Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$285.14 M
|
$117.01 M
|
$89.79 M
|
$75.68 M
|
$57.26 M
|
$49.13 M
|
$23.59 M
|
| Cost of Revenue |
$164.67 M |
$65.36 M |
$313.35 M |
$232.16 M |
$0.00 |
$0.00 |
-$96,000.00 |
| Gross Profit |
$120.48 M |
$51.64 M |
-$223.55 M |
-$156.48 M |
$57.26 M |
$49.13 M |
$23.69 M |
| Gross Profit Ratio |
0.42 |
0.44 |
-2.49 |
-2.07 |
1 |
1 |
1 |
| Research and Development
Expenses |
$382.22 M
|
$335.65 M
|
$313.35 M
|
$232.16 M
|
$161.94 M
|
$60.64 M
|
$8.20 M
|
| General & Administrative
Expenses |
$106.77 M
|
$80.63 M
|
$46.94 M
|
$23.15 M
|
$6.75 M
|
$2.77 M
|
$1.62 M
|
| Selling & Marketing
Expenses |
$94.16 M
|
$93.42 M
|
$102.54 M
|
$49.57 M
|
$25.62 M
|
$1.16 M
|
-$217,000.00
|
| Selling, General &
Administrative Expenses |
$180.48 M
|
$174.05 M
|
$149.48 M
|
$72.72 M
|
$32.37 M
|
$3.93 M
|
$1.40 M
|
| Other Expenses |
-$28.24 M |
$2.23 M |
-$6.07 M |
-$74.21 M |
-$1.68 M |
-$2,000.00 |
$0.00 |
| Operating Expenses |
$562.69 M |
$509.70 M |
$462.83 M |
$304.88 M |
$192.63 M |
$64.21 M |
$9.60 M |
| Cost And Expenses |
$727.36 M |
$575.06 M |
$462.83 M |
$304.88 M |
$192.63 M |
$64.21 M |
$9.81 M |
| Interest Income |
$54.49 M |
$8.18 M |
$971,000.00 |
$2.93 M |
$4.58 M |
$6.21 M |
$1,000.00 |
| Interest Expense |
$21.79 M |
$10.80 M |
$900,000.00 |
$4.21 M |
$223,000.00 |
$82,000.00 |
$0.00 |
| Depreciation &
Amortization |
$20.45 M
|
$18.39 M
|
$13.92 M
|
$9.93 M
|
$5.26 M
|
$1.68 M
|
$217,000.00
|
| EBITDA |
-$421.77 M
|
-$437.44 M
|
-$379.11 M
|
-$303.41 M
|
-$125.61 M
|
-$7.18 M
|
$14.00 M
|
| EBITDA Ratio |
-1.48 |
-3.74 |
-4.22 |
-4.01 |
-2.19 |
-0.15 |
0.59 |
| Operating Income Ratio
|
-1.55
|
-3.9
|
-4.38
|
-4.14
|
-2.29
|
-0.03
|
0.58
|
| Total Other
Income/Expenses Net |
-$77.90 M
|
$10.10 M
|
$6.82 M
|
$5.72 M
|
$501,000.00
|
$7.32 M
|
$56,000.00
|
| Income Before Tax |
-$520.12 M |
-$445.72 M |
-$386.21 M |
-$307.62 M |
-$130.37 M |
-$1.62 M |
$13.84 M |
| Income Before Tax Ratio
|
-1.82
|
-3.81
|
-4.3
|
-4.06
|
-2.28
|
-0.03
|
0.59
|
| Income Tax Expense |
-$1.86 M |
$625,000.00 |
$1,000.00 |
-$4.15 M |
$2.60 M |
$1.17 M |
$4.47 M |
| Net Income |
-$518.25 M |
-$446.35 M |
-$386.21 M |
-$303.48 M |
-$132.97 M |
-$2.78 M |
$9.37 M |
| Net Income Ratio |
-1.82 |
-3.81 |
-4.3 |
-4.01 |
-2.32 |
-0.06 |
0.4 |
| EPS |
-2.94 |
-2.81 |
-2.74 |
-2.57 |
-1.01 |
-0.0278 |
0.0709 |
| EPS Diluted |
-2.94 |
-2.81 |
-2.74 |
-2.57 |
-1.01 |
-0.0278 |
0.0709 |
| Weighted Average Shares
Out |
$176.08 M
|
$159.04 M
|
$140.85 M
|
$118.15 M
|
$132.01 M
|
$100.00 M
|
$132.01 M
|
| Weighted Average Shares
Out Diluted |
$176.08 M
|
$159.04 M
|
$140.85 M
|
$118.15 M
|
$132.01 M
|
$100.21 M
|
$132.01 M
|
| Link |
|
|
|
|
|
|
|
